Conclusions: Wednesday morning’s General Session 2 featured findings from three trials looking at the use of the antibody drug conjugate (ADC) trastuzumab deruxtecan (T-DXd) in HER2-positive metastatic and HER-2-low, HR-positive early-stage breast cancer.

Conclusions: The patient was treated with first-line Abemaciclib plus letrozole and achieved a rapid partial response with sudden clinical stabilization. Although the patient did not technically present with a visceral crisis, this case presentation also endorsed the upfront use of CDK4/6 inhibitor combinations in critical clinical situations in...

Conclusions: This study provides researchers with a reliable basis and guidance for finding authoritative references, understanding research trends, and mining research neglect directions.

Trastuzumab deruxtecan (TDXd) in the second line for metastatic HER2 positive breast cancer shows improved overall survival over T-DM1 continued PFS benefit after longer follow up. This abstract was also presented at SABCS 2022.

Conclusions: Simulation gives a road map for future discussions about developing improved early detection approaches that holds greater potential in increasing the survival rate of cancer patients. The different computational techniques can be a new dominion among researchers and combating the challenges associated with breast cancer.